Antifibrotic effect of disulfiram on bleomycin-induced lung fibrosis in mice and its impact on macrophage infiltration
Open accessPublished version of a preprint
Abstract
Abstract Macrophage accumulation in the lung tissue during inflammation is important in the pathogenesis of fibrotic lung disease. Deficiencies in chemokine receptors CCR2 and CCR5 and their ligands, which mediate monocyte/macrophage migration, ameliorate bleomycin (BLM)-induced lung fibrosis. Disulfiram (DSF)—used as a drug for alcoholism because of its aldehyde dehydrogenase (ALDH)-inhibiting effect—inhibits monocyte/macrophage migration by inhibiting FROUNT, an intracellular regulator of CCR2/CCR5 signaling. To examine DSF’s antifibrotic effect on BLM-induced lung fibrosis in mice and its impact on macrophage response, oral DSF administration’s effects on lung fibrosis and macrophage infiltration were evaluated in a BLM-induced lung fibrosis mouse model. The DSF direct inhibitory activity on monocyte migration was measured in a Boyden chamber assay and compared with DSF-related inhibitors with different FROUNT-inhibition activities. Quantitative PCR determined the expression of fibrosis-promoting genes in the lung tissue. DSF suppressed macrophage infiltration into the lung tissue and significantly attenuated BLM-indued lung fibrosis. DSF and DSF metabolites, diethyldithiocarbamate (DDC) and copper diethyldithiocarbamate (Cu(DDC)2), inhibited monocyte migration toward the culture supernatant fluid of primary mouse lung cells comprising mainly CCL2, whereas cyanamide—another ALDH inhibitor—did not. DSF, with higher inhibitory activity against FROUNT than DDC and Cu(DDC)2, inhibited monocyte migration most strongly. In BLM-induced fibrotic lung tissues, profibrotic factors were highly expressed but were reduced by DSF treatment. These results suggest DSF inhibited macrophage infiltration probably by a FROUNT-mediated mechanism and attenuated BLM-induced lung fibrosis. DSF therapy as drug repositioning can be practical and feasible for treating fibrotic lung diseases, including idiopathic pulmonary fibrosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DIS inhibits macrophage infiltration, likely via FROUNT suppression, CCR2/CCR5 signaling, and attenuates bleomycin-induced lung fibrosis.
“It inhibits macrophage infiltration, likely via FROUNT suppression, an intracellular regulator of chemokine receptors, chemokine receptor 2 (CCR2)/C-C motif chemokine receptor 5 (CCR5) signaling, and attenuates bleomycin-induced lung fibrosis.121”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [121]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908 · see citing works
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269 · see citing works
Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
Ashcroft, T., Simpson, J. M., & Timbrell, V. (1988) · Journal of Clinical Pathology · doi:10.1136/jcp.41.4.467 · Cited by 1,692 · see citing works
Serbina, N. V., & Pamer, E. G. (2006) · Nature Immunology · doi:10.1038/ni1309 · Cited by 1,658 · see citing works
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation
Hu, J. J., Liu, X., Xia, S., Zhang, Z., Zhang, Y., Zhao, J., Ruan, J., Luo, X., Lou, X., Bai, Y., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0669-6 · Cited by 1,145 · see citing works
Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span
Misharin, A. V., Morales-Nebreda, L., Reyfman, P. A., Cuda, C. M., Walter, J. M., McQuattie-Pimentel, A. C., Chen, C.-I., Anekalla, K. R., Joshi, N., Williams, K. J. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162152 · Cited by 1,133 · see citing works
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056 · see citing works
Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis
Morse, C., Tabib, T., Sembrat, J., Buschur, K. L., Bittar, H. E. T., Valenzi, E., Jiang, Y., Kass, D. J., Gibson, K. F., Chen, W., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.02441-2018 · Cited by 832 · see citing works
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Skrott, Z., Mistrik, M., Andersen, K. K., Friis, S., Majera, D., Gursky, J., Ozdian, T., Bartkova, J., Turi, Z., Moudry, P., et al. (2017) · Nature · doi:10.1038/nature25016 · Cited by 807 · see citing works
Defects in Macrophage Recruitment and Host Defense in Mice Lacking the CCR2 Chemokine Receptor
Kurihara, T., Warr, G. A., Loy, J. K., & Bravo, R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.10.1757 · Cited by 717 · see citing works
Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis
Pardo, A., Gibson, K. F., Cisneros, J., Richards, T. J., Yang, Y., Becerril, C., Yousem, S., Herrera, I., Ruiz, V., Selman, M., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020251 · Cited by 492 · see citing works
Expression and Characterization of the Chemokine Receptors CCR2 and CCR5 in Mice
Mack, M., Cihak, J., Simonis, C., Luckow, B., Proudfoot, A. E. I., Plachý, J., Brühl, H., Frink, M., Anders, H., Vielhauer, V., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.7.4697 · Cited by 459 · see citing works
CCR2-Mediated Recruitment of Fibrocytes to the Alveolar Space after Fibrotic Injury
Moore, B. B., Kolodsick, J. E., Thannickal, V. J., Cooke, K. R., Moore, T. A., Hogaboam, C. M., Wilke, C. A., & Toews, G. B. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62289-4 · Cited by 440 · see citing works
Selman, M., Ruiz, V., Cabrera, S., Segura, L., Ramı́rez, R., Barrios, R. J., & Pardo, A. (2000) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2000.279.3.l562 · Cited by 426 · see citing works
Kaminski, N., Allard, J. D., Pittet, J., Zuo, F., Griffiths, M., Morris, D. G., Huang, X., Sheppard, D., & Heller, R. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1778 · Cited by 416 · see citing works
Macrophages: friend or foe in idiopathic pulmonary fibrosis?
Zhang, L., Wang, Y., Wu, G., Xiong, W., Gu, W., & Wang, C. (2018) · Respiratory Research · doi:10.1186/s12931-018-0864-2 · Cited by 368 · see citing works
Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · PubMed · Cited by 358 · see citing works
Immune mechanisms in pulmonary fibrosis
Kolahian, S., Fernandez, I. E., Eickelberg, O., & Hartl, D. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0121tr · Cited by 349 · see citing works
(1999) · PubMed · Cited by 207 · see citing works
Cu/Zn Superoxide Dismutase Plays Important Role in Immune Response
Marikovsky, M., Ziv, V., Nevo, N., Harris‐Cerruti, C., & Mahler, O. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.2993 · Cited by 206 · see citing works
Baran, C. P., Opalek, J. M., McMaken, S., Newland, C. A., O’Brien, J. M., Hunter, M. G., Bringardner, B. D., Monick, M. M., Brigstock, D. R., Stromberg, P. C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200609-1279oc · Cited by 196 · see citing works
Deletion of c-FLIP from CD11bhi Macrophages Prevents Development of Bleomycin-induced Lung Fibrosis
McCubbrey, A. L., Barthel, L., Mohning, M. P., Redente, E. F., Mould, K. J., Thomas, S. M., Leach, S. M., Danhorn, T., Gibbings, S. L., Jakubzick, C. V., et al. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0154oc · Cited by 195 · see citing works
Okuma, T., Terasaki, Y., Kaikita, K., Kobayashi, H., Kuziel, W. A., Kawasuji, M., & Takeya, M. (2004) · The Journal of Pathology · doi:10.1002/path.1667 · Cited by 189 · see citing works
Self-citationBonecchi, R., Polentarutti, N., Luini, W., Borsatti, A., Bernasconi, S., Locati, M., Power, C., Proudfoot, A. E. I., Wells, T. N. C., Mackay, C. R., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.1.474 · Cited by 187 · see citing works
Gurujeyalakshmi, G., Hollinger, M. A., & Giri, S. N. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.276.2.l311 · Cited by 180 · see citing works
Surfactant proteins A and D: disease markers
Kuroki, Y., Takahashi, H., Chiba, H., & Akino, T. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00079-9 · Cited by 179 · see citing works
Ishida, Y., Kimura, A., Kondo, T., Hayashi, T., Ueno, M., Takakura, N., Matsushima, K., & Mukaida, N. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.051213 · Cited by 170 · see citing works
Self-citationRole of Osteopontin in the Pathogenesis of Bleomycin-Induced Pulmonary Fibrosis
Takahashi, F., Takahashi, K., Okazaki, T., Maeda, K., Ienaga, H., Maeda, M., Kon, S., Uede, T., & Fukuchi, Y. (2001) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.24.3.4293 · Cited by 160 · see citing works
Oku, H., Nakazato, H., Horikawa, T., Tsuruta, Y., & Suzuki, R. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01757-0 · Cited by 158 · see citing works
High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis.
Harrison, J. H., & Lazo, J. S. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39287-6 · Cited by 150 · see citing works
Novel Chemokine Responsiveness and Mobilization of Neutrophils during Sepsis
Speyer, C. L., Gao, H., Rancilio, N. J., Neff, T. A., Hu, B., Sarma, J. V., & Ward, P. A. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63268-3 · Cited by 146 · see citing works
Disulfiram induces apoptosis in human melanoma cells: a redox-related process.
Cen, D., Gonzalez, R. I., Buckmeier, J. A., Kahlon, R. S., Tohidian, N. B., & Meyskens, F. L. (2002) · PubMed · Cited by 145 · see citing works
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab
Raghu, G., Martínez, F. J., Brown, K. K., Costabel, U., Cottin, V., Wells, A. U., LANCASTER, L. H., Gibson, K. F., Haddad, T., Agarwal, P., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01558-2014 · Cited by 144 · see citing works
Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis
Terashima, Y., Onai, N., Murai, M., Enomoto, M., Poonpiriya, V., Hamada, T., Motomura, K., Suwa, M., Ezaki, T., Haga, T., et al. (2005) · Nature Immunology · doi:10.1038/ni1222 · Cited by 117 · see citing works
Self-citationZhang, W., Ohno, S., Steer, B., Klee, S., Staab-Weijnitz, C. A., Wagner, D. E., Lehmann, M., Stoeger, T., Königshoff, M., & Adler, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01216 · Cited by 104 · see citing works
Targeting FROUNT with Disulfiram Regulates Macrophage Responses in Cancer
Terashima, Y., Toda, E., Itakura, M., Otsuji, M., Yoshinaga, S., Okumura, K., Shand, F. H. W., Komohara, Y., Takeda, M., Kokubo, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-020-14338-5 · Cited by 102 · see citing works
Self-citationInhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells
Duan, L., Shen, H., Zhao, G., Yang, R., Cai, X., Zhang, L., Jin, C., & Huang, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.047 · Cited by 95 · see citing works
S100A4+ Macrophages Are Necessary for Pulmonary Fibrosis by Activating Lung Fibroblasts
Li, Y., Bao, J., Bian, Y., Erben, U., Wang, P., Song, K., Liu, S., Li, Z., Gao, Z., & Qin, Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01776 · Cited by 88 · see citing works
Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
van Geffen, C., Deißler, A., Quante, M., Renz, H. E., Hartl, D., & Kolahian, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663203 · Cited by 80 · see citing works
Timp-1 is a Key Factor of Fibrogenic Response to Bleomycin in Mouse Lung
Manoury, B., Caulet-Maugendre, S., Guénon, I., Lagente, V., & Boichot, E. (2006) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200601900303 · Cited by 77 · see citing works
Hou, J., Ji, J., Chen, X., Cao, H., Tan, Y., Cui, Y., Xiang, Z., & Han, X. (2020) · FEBS Journal · doi:10.1111/febs.15669 · Cited by 66 · see citing works
Overview — In vitro inhibition of aldehyde dehydrogenase by disulfiram and metabolites
Lipsky, J. J., Shen, M. L., & Naylor, S. (2001) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00224-6 · Cited by 65 · see citing works
Superoxide scavenging activity of pirfenidone–iron complex
Mitani, Y., Sato, K., Muramoto, Y., Karakawa, T., Kitamado, M., Iwanaga, T., Nabeshima, T., Maruyama, K., Nakagawa, K., Ishida, K., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.093 · Cited by 65 · see citing works
Brieland, J. K., Jones, M. L., Clarke, S. J., Baker, J. B., Warren, J. S., & Fantone, J. C. (1992) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb/7.2.134 · Cited by 61 · see citing works
Repurposing disulfiram for treatment of Staphylococcus aureus infections
Thakare, R., Shukla, M., Kaul, G., Dasgupta, A., & Chopra, S. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.03.024 · Cited by 52 · see citing works
Zhao, M., Sun, D., Guan, Y., Wang, Z., Sang, D., Liu, M., Pu, Y., Fang, X., Wang, D., Huang, A., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4587-15.2016 · Cited by 48 · see citing works
FROUNT Is a Common Regulator of CCR2 and CCR5 Signaling to Control Directional Migration
Toda, E., Terashima, Y., Sato, T., Hirose, K., Kanegasaki, S., & Matsushima, K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803469 · Cited by 44 · see citing works
Self-citationTREATMENT OF ALCOHOLISM WITH TETRAETHYLTHIURAM DISULFIDE (Antabus®)
Jacobsen, E. (1949) · JAMA · doi:10.1001/jama.1949.02900310022006 · Cited by 42 · see citing works
Gandhi, N. M., Gopalaswamy, U. V., & Nair, C. K. K. (2003) · Journal of Radiation Research · doi:10.1269/jrr.44.255 · Cited by 25 · see citing works
Overview of Antabuse® (Disulfiram) in Radiation and Cancer Biology
Jia, Y., & Huang, T. (2021) · Cancer Management and Research · doi:10.2147/cmar.s308168 · Cited by 15 · see citing works
Jiang, H., Zhao, Y., Tang, H., Duan, S., Li, M., Yang, X., Liu, J., Lou, X., Cai, Y., Zhao, W., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105923 · Cited by 12 · see citing works
Fujisawa, Y., Matsuda, K., & Uehara, T. (2020) · Biological Chemistry · doi:10.1515/hsz-2020-0125 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Lu, W., Teoh, A. K. Y., Waters, M., Haug, G., Shakeel, I., Hassan, M. I., Shahzad, A. M., Larsson‐Callerfelt, A., Piccari, L., & Sohal, S. S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108757 · Cited by 34 · see citing works
The role of macrophages in asthma-related fibrosis and remodelling
Yang, X., Li, F., Zhang, G., Foster, P. S., & Yang, M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108820 · Cited by 20 · see citing works
Samuel, V. P., Afzal, M., Babu, M. A., Malathi, H., Maharana, L., Pandey, S. N., Ali, H., Almalki, W. H., Almujri, S. S., & Kumar, K. B. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-02083-4 · Cited by 15 · see citing works
Tarantino, G., & Citro, V. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.119467 · Cited by 14 · see citing works
The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer
Chandra, R., Ehab, J., Hauptmann, E., Gunturu, N. S., Karalis, J. D., Kent, D. O., Heid, C. A., Reznik, S. I., Sarkaria, I. S., Huang, H., et al. (2025) · Cancers · doi:10.3390/cancers17111732 · Cited by 10 · see citing works
Repurposing disulfiram: targeting Zeb1 to attenuate paraquat-induced pulmonary fibrosis in rats
Karimzadeh, F., Daraei, A., Zabihi-Neyshaburi, E., Feizi, F., Ranaee, M., Khafri, S., Esmaeili, Z., & Babazadeh, Z. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-025-10613-1 · Cited by 3 · see citing works
Lema, D. A., Lopez, E. K., Lam, J. R., Tskhakaia, I., González-Moret, Y. A., & Abdollahi, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136538 · Cited by 2 · see citing works
Targeting cu metabolism as a potential therapeutic strategy for pulmonary fibrosis
Li, B., Zhang, M., Cai, J., Li, N. S., Li, X.-H., & Cheng, H. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189379 · Cited by 2 · see citing works
Benkő, B.-M., De Brito Parreirinha, N. S., Sebe, I., & Zelkó, R. (2026) · iScience · doi:10.1016/j.isci.2026.115441 · Cited by 2 · see citing works
Liu, X., & Chai, G. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126833 · Cited by 1 · see citing works
Komeno, M., Ohta, A., Tanabe, N., Abe, H., Terashima, Y., Saitoh, A., & Higashi, K. (2025) · Journal of Chromatography B · doi:10.1016/j.jchromb.2025.124568 · Cited by 1 · see citing works
Self-citationSun, C.-Y., Yang, W., Shen, H., Yu, W.-K., Chen, W.-C., & Yang, K. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s569219
Esmaeili, M., Daraei, A., Najafzadehvarzi, H., Khafri, S., Esmaeili, Z., Beheshti, Y., & Babazadeh, Z. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-13055-4
Serum protein biomarkers for polymyalgia rheumatica: a case-control study
Furukawa, H., Hikichi, Y., Kunieda, K., Oka, S., Higuchi, T., Tohma, S., & Itoh, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1948036
- Authors
- Okabe, Y., Toda, E., Urushiyama, H., Terashima, Y., Kunugi, S., Kajimoto, Y., Terasaki, M., Matsushima, K., Saito, A., Yamauchi, Y., Nagase, T., Shimizu, A., & Terasaki, Y.
- Affiliations
- The University of Tokyo (JP)
- Tokyo University of Science (JP)
- Nippon Medical School (JP)
- Tokyo University of Foreign Studies (JP)
- Nippon Medical School Hospital (JP)
- Corresponding author
- Terasaki, Yasuhiro
- ORCID
- Venue
- Scientific Reports
- Published
- 2024-10-10
- Volume
- 14
- Issue
- 1
- Pages
- 23653-23653
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC11464646
- OpenAlex
- W4403314383
- Cited by
- 14
- References
- 52
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 1
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-nd)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (20K07553, 21H02755, 18K08140, 20K08553)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
- Keywords
- disulfiram, bleomycin-induced lung fibrosis, pulmonary fibrosis, macrophage infiltration, monocyte migration, aldehyde dehydrogenase inhibition, diethyldithiocarbamate, S100A4, idiopathic pulmonary fibrosis, drug repurposing, macrophage-targeted therapy
- MeSH terms
- Antifibrotic Agents, Animals, Bleomycin, Cell Movement, Disease Models, Animal, Disulfiram, Lung, Macrophages, Male, Mice, Inbred C57BL, Monocytes, Pulmonary Fibrosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
